Literature DB >> 15557364

Control of plasma nitric oxide bioactivity by perfluorocarbons: physiological mechanisms and clinical implications.

Olga Rafikova1, Elena Sokolova, Ruslan Rafikov, Evgeny Nudler.   

Abstract

BACKGROUND: Perfluorocarbons (PFCs) are promising blood substitutes because of their chemical inertness and unparalleled ability to transport and upload O2 and CO2. Here, we report that PFC emulsions also efficiently absorb and transport nitric oxide (NO). METHODS AND
RESULTS: Accumulation of NO and O2 in PFC micelles results in rapid NO oxidation and generation of reactive NO(x) species. Such micellar catalysis of NO oxidation leads to formation of vasoactive S-nitrosothiols (RSNO) in vitro and in vivo as detected electrochemically. The efficiency of PFC-mediated S-nitrosation depends on the amount of PFC in aqueous solution. The optimal PFC concentration that produced the maximum level of RSNO was approximately 1% (vol/vol). Larger PFC amounts were progressively less efficient in generating RSNO and functioned simply as NO sink. These results explain the characteristic hemodynamic effects of PFCs. Intravenous bolus application of PFC (0.14 g/kg, approximately 1% vol/vol) to Wistar-Kyoto rats decreased mean arterial pressure significantly (-10 mm Hg over 40 minutes). PFC-induced hypotension could be further stimulated (-17 mm Hg over 140 minutes) by exogenous thiols (cysteine and glutathione). In contrast, a larger amount of PFC (1 g/kg, approximately 7% vol/vol) exhibited a strong hypertensive effect (11 mm Hg over 40 minutes).
CONCLUSIONS: The present study reveals a physiologically significant pool of endogenous plasma NO and underscores the crucial role of the circulating hydrophobic phase in modulating its bioactivity. The results also establish PFC as a conceptually new pharmacological tool for various cardiovascular complications associated with NO imbalance.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15557364     DOI: 10.1161/01.CIR.0000148782.37563.F8

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  8 in total

Review 1.  Blood substitutes: evolution from noncarrying to oxygen- and gas-carrying fluids.

Authors:  Pedro Cabrales; Marcos Intaglietta
Journal:  ASAIO J       Date:  2013 Jul-Aug       Impact factor: 2.872

2.  Fluorine (19F) MRS and MRI in biomedicine.

Authors:  Jesús Ruiz-Cabello; Brad P Barnett; Paul A Bottomley; Jeff W M Bulte
Journal:  NMR Biomed       Date:  2010-09-15       Impact factor: 4.044

3.  Assessment of nitric oxide signals by triiodide chemiluminescence.

Authors:  Alfred Hausladen; Ruslan Rafikov; Michael Angelo; David J Singel; Evgeny Nudler; Jonathan S Stamler
Journal:  Proc Natl Acad Sci U S A       Date:  2007-02-07       Impact factor: 11.205

4.  Transport of nitric oxide by perfluorocarbon emulsion.

Authors:  Daniel Ortiz; Pedro Cabrales; Juan C Briceño
Journal:  Biotechnol Prog       Date:  2013-09-10

5.  Postprandial lipids accelerate and redirect nitric oxide consumption in plasma.

Authors:  Kurt Vrancken; Hobe J Schroeder; Lawrence D Longo; Gordon G Power; Arlin B Blood
Journal:  Nitric Oxide       Date:  2016-03-25       Impact factor: 4.427

6.  The intravenous perfluorocarbon emulsion Oxycyte does not increase hyperbaric oxygen-related seizures in a non-sedated swine model.

Authors:  Richard T Mahon; Aaron Hall; Michael Bodo; Charles Auker
Journal:  Eur J Appl Physiol       Date:  2013-09-06       Impact factor: 3.078

7.  Safety of poly (ethylene glycol)-coated perfluorodecalin-filled poly (lactide-co-glycolide) microcapsules following intravenous administration of high amounts in rats.

Authors:  Katja B Ferenz; Indra N Waack; Julia Laudien; Christian Mayer; Martina Broecker-Preuss; Herbert de Groot; Michael Kirsch
Journal:  Results Pharma Sci       Date:  2014-04-30

Review 8.  Perfluorocarbon-based oxygen carriers: from physics to physiology.

Authors:  Johannes Jägers; Anna Wrobeln; Katja B Ferenz
Journal:  Pflugers Arch       Date:  2020-11-03       Impact factor: 3.657

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.